Aachen (ots) - The German pharmaceutical company Grunenthal
announces its worldwide exclusive rights on trimegestone for the use
in oral contraception by Aventis Pharma, SA, France, a subsidiary of
sanofi-aventis. Thereby the firm extends its gynaecological pipeline.
Trimegestone will be developed as a new oral contraceptive component
derived from natural progesterone.
The agreement grants Grunenthal exclusive access to mainly
preclinical data on trimegestone for the development of an oral
contraceptive. Moreover it secures a mutually exclusive supply
agreement: While Aventis Pharma, SA, holds the patent on the
manufacturing synthesis process and provides for the production of
the active ingredient trimegestone, Grunenthal will take care for the
formulation, the clinical development, registration, and marketing.
"With the development of a trimegestone containing oral
contraceptive Grunenthal shows its strong commitment to become a
major player in the field of gynaecology in the mid term", says Prof.
Dr. Eric-Paul Pâques, member of the Executive Board of Grunenthal."
About Trimegestone Trimegestone is a metabolically neutral &
naturally derived progesterone agonist, thus long term acceptance for
female users is expected. Due to its favorable metabolic safety
profile trimegestone is already in use in hormone replacement
therapy. In this respect trimegestone is an ideal progestogen to be
used in hormonal contraception.
About Grunenthal Grunenthal is an expert in pain therapy and
gynaecology and a pioneer in intelligent, user-friendly drug delivery
technologies. Founded in 1946, the company employs 1,900 people in
Germany and 4,800 worldwide. In 2006, Grunenthal achieved revenues of
813 million Euro.
ots Originaltext: Grünenthal GmbH
Im Internet recherchierbar: http://www.presseportal.ch
Phone: +49 241 569-2858,
Fax: +49 241 569-1486,
52099 Aachen, Germany,